Medical NewsGerman Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | 5HT1-agonists |
| Generic Name : | Eletriptan |
| Drug description : | Round, film coated, convex orange tablets marked 'REP 20' or 'REP 40' on one side and Pfizer on the other side. |
| Presentation : | Tablets, eletriptan (as hydrobromide) 20mg, 40mg. |
| Indications : | Acute treatment of the headache phase of migraine attacks, with or without aura. |
| Adult Dosage : | Recommended initial dose, 40mg, taken as early as possible after onset of migraine headache. If migraine recurs within 24 hours, repeat dose after a minimum of two hours. If no response to first dose within two hours, a second dose should not be taken for the same attack. Maximum daily dose, 80mg. |
| Child Dosage : | Under 17 years, not recommended |
| Elderly Dosage : | Over 65 years, not recommended |
| Contra Indications : | Hypersensitivity to eletriptan hydrobromide or to any of the excipients. Severe hepatic or renal impairment. Moderately severe or severe hypertension, untreated mild hypertension. Confirmed coronary heart disease, including ischaemic heart disease (angina pectoris, previous myocardila infarction or confirmed silent ischaemia), objective or subjective symptoms of ischaemic heart disease, or Prinzmetal's angina. Significant arrhythmias or heart failaure. Peripheral vascular disease. History of cerebrovascular accident (CVA) or transiaent ischaemic attack (TIA). Administration of ergotamine or derivatives (including methysergide) within 24 hours before or after treatment with eletriptan. Concomitant administration of other 5HT1 - agonists. |
| Special Precautions : | For use only when a clear diagnosis of migraine is established. Not recommended for hemiplegic, ophthalmoplegic or basilar migraine, or for the treatment of atypical headaches. Not to be given without prior evaluation to patients in whom unrecognised cardiac disease is likely, or patients at risk of coronary artery disease (eg, patients with hypertension, diabetes or a strong history of CAD, smokers or patients using nicotine replacement products, men over 40 years of age, postmenopausal woman). Mild or moderate renal impairment; reduce dose (contraindicated in severe impairment). Pregnancy and lactation. Not to be given together with potent CYP3A4 inhibitors; see Interactions. |
| Interactions : | Ergotamine, ergot derivatives (including methysergide), other 5HT1-agonists; concomitant use contraindicated. Potent CYP3A4 inhibitors such as ketoconazole, itraconazole, erythromycin, clarithromycin, protease inhibitors (ritonavir, indinavir, nelfinavir). St John's Wort (hypericum perforatum). |
| Adverse Reactions : | Most commonly, asthenia, somnolence, nausea and dizziness. Also chest symptoms (pain, tightness, pressure), headache, abdominal pain, back pain, chills, throat tightness, sensation of warmth or flushing, palpition, tachycardia, dry mouth, dyspepsia, myasthenia, myalgia, tingling or abnormal sensation, sensation of tightness or stiffness, hypoaesthesia, vertigo, pharyngitis, sweating. |
| Manufacturer : | Pfizer |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org